Edgewise Therapeutics (EWTX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.53
- Estimate
- -$0.47
- Surprise
- -12.2%
- Score today
- 4.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Edgewise Therapeutics (EWTX) reported a wider loss than forecast — diluted EPS of -$0.53 against the -$0.47 estimate (a 12.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates EWTX Sell at 4.7/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -12.2% surprise compares with a -2.6% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: sevasemten and EDG-7500
- Quality below floor (1.6 < 4.0)
- Momentum score 2.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $42.12
- Price target
- $44.97
- Stop
- $39.42
- Upside to target
- +6.8%
- Reward-to-risk
- 0.7:1
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
EWTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $4.56B
- P/E (fwd)
- -23.1
- 52-week range
- $13.69–$48.40
- Off 52-week high
- 13.0%
- RSI (14)
- 41
- Volume vs avg
- 0.09×
- Score today
- 4.7/10